Regen BioPharma, Inc.
RGBP
$0.026
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| SG&A Expenses | 504.80K | 539.50K | 487.10K | 501.00K | 471.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 538.30K | 605.50K | 593.20K | 654.60K | 627.40K |
| Operating Income | -301.90K | -369.10K | -356.90K | -418.30K | -391.00K |
| Income Before Tax | -967.00K | -929.80K | -1.03M | -662.40K | -722.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.97 | -0.93 | -1.03 | -0.66 | -0.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -967.00K | -929.80K | -1.03M | -662.40K | -722.50K |
| EBIT | -301.90K | -369.10K | -356.90K | -418.30K | -391.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.16 | -0.19 | -0.22 | -0.13 | -0.14 |
| Normalized Basic EPS | -0.10 | -0.12 | -0.13 | -0.08 | -0.09 |
| EPS Diluted | -0.16 | -0.19 | -0.22 | -0.13 | -0.14 |
| Normalized Diluted EPS | -0.10 | -0.12 | -0.13 | -0.08 | -0.09 |
| Average Basic Shares Outstanding | 58.45M | 38.91M | 21.47M | 20.96M | 20.00M |
| Average Diluted Shares Outstanding | 58.45M | 38.91M | 21.47M | 20.96M | 20.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |